Surgical Science Sweden AB (publ): Interim report January – September 2026: Increasing profitability and important strategic progress

By Modular Finance

Third quarter 2026 (July – September)

  • Net sales amounted to SEK 260.2 (263.6) million, a decrease of 1 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales also decreased by 1 percent.
  • License revenue amounted to SEK 76.0 (65.5) million and accounted for 29 (25) percent of net sales.
  • The gross margin was 68 (65) percent.
  • Operating profit amounted to SEK 32.0 (27.2) million.
  • Net profit amounted to SEK 34.1 (20.4) million, corresponding to earnings per share of SEK 0.67 (0.40).
  • Cash flow from operating activities amounted to SEK 42.5 (-4.4) million. As at September 30, 2026, cash and cash equivalents amounted to SEK 674.9 (597.4) million.

First nine months of 2026 (January – September)

  • Net sales amounted to SEK 750.2 (723.5) million, an increase of 4 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 5 percent.
  • License revenue amounted to SEK 228.4 (208.3) million and accounted for 30 (29) percent of net sales.
  • The gross margin was 68 (66) percent.
  • Operating profit amounted to SEK 87.5 (28.7) million.
  • Net profit amounted to SEK 73.6 (33.6) million, corresponding to earnings per share of SEK 1.44 (0.66).
  • Cash flow from operating activities amounted to SEK 123.1 (6.9) million.

Gothenburg, Sweden, November 12, 2026
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases
https://surgicalscience.com/aktien/financial-report

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.